Oncologia

Estudo randomizado | Aumolertinibe vs. gefitinibe como terapia de primeira linha para câncer de pulmão de não pequenas células localmente avançado ou metastático com deleção do EGFR Exon 19 ou mutações L858R.

27 Mai, 2022 | 13:10h

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations – Journal of Clinical Oncology

 

Comentário no Twitter

Aumolertinib (a 3rd gen TKI) is effective in the first-line treatment of EGFR-mutant NSCLC-AENEAShttps://t.co/QL6xXptxFa pic.twitter.com/grIbapsxzU

— K Pavithran (@drkpavithran) May 18, 2022

Sob licença de: https://creativecommons.org/licenses/by-nc-nd/4.0/

---

Estudo randomizado | Adição de metformina à terapia padrão não melhora os desfechos em pacientes com câncer de mama.

26 Mai, 2022 | 13:31h

Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial – JAMA (gratuito por tempo limitado)

Editorial: Who Will Benefit From Metformin? – JAMA Oncology

Comunicado de imprensa: Common diabetes drug not effective against early-stage breast cancer, landmark trial reveals – Lunenfeld-Tanenbaum Research Institute

---

Estudo de coorte | Risco de tromboembolismo venoso em homens com câncer de próstata em comparação com homens na população geral.

26 Mai, 2022 | 12:56h

Risk of venous thromboembolism in men with prostate cancer compared with men in the general population: a nationwide population-based cohort study in Sweden – BMJ Open

Comunicado de imprensa: Men with prostate cancer have a higher risk of serious blood clots – BMJ

 

Comentário no Twitter

Men with prostate cancer have a 50% higher risk of developing venous thrombosis during the 5 years following their cancer diagnosishttps://t.co/RrYAB5lSrb pic.twitter.com/VGMI7GILgE

— K Pavithran (@drkpavithran) May 24, 2022

Sob licença de http://creativecommons.org/licenses/by-nc/4.0/

---

Estudo randomizado | Everolimo não é benéfico quando adicionado à terapia endócrina adjuvante para pacientes com câncer de mama primário positivo para receptor de hormônio de alto risco e negativo para receptor 2 do fator de crescimento epidérmico humano.

26 Mai, 2022 | 12:53h

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer – Journal of Clinical Oncology

 

Comentários no Twitter

Previously presented @myESMO VP, the #UNIRAD RCT of adjuvant everolimus in high-risk EBC is now published on @JCO_ASCO. Trial stopped for futility: everolimus didn’t improve DFS & was poorly tolerated. Large research effort answering an important question.https://t.co/wmYLWpDWTC

— Paolo Tarantino (@PTarantinoMD) May 24, 2022

Everolimus added to adjuvant ET fails to improve DFS in patients with high-risk HR+ve, HER2 neg primary breast cancer; poorly tolerated -53.4% discontinuation ratehttps://t.co/lmq2jhbhCO

— K Pavithran (@drkpavithran) May 24, 2022

 

---

Estudo randomizado | Efeito do denosumabe adicionado a dois regimes diferentes com nab-paclitaxel como terapia neoadjuvante em pacientes com câncer de mama primário.

26 Mai, 2022 | 12:51h

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

In a randomized clinical trial in 780 pts with #breastcancer, addition of denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy with two different nab-paclitaxel schedules did not increase the pCR rate (41% vs 43% without denosumab): https://t.co/gPu6hrSp7z #bcsm

— NatureRevClinOncol (@NatRevClinOncol) May 24, 2022

 

---

Avaliação de tecnologia em saúde | Teste molecular para nódulos de tireoide de citologia indeterminada.

26 Mai, 2022 | 12:43h

Molecular Testing for Thyroid Nodules of Indeterminate Cytology: A Health Technology Assessment – Ontario Health Technology Assessment Series

---

Diretriz de pesquisa ASCO | Aumento da diversidade étnica e racial nos estudos clínicos oncológicos.

25 Mai, 2022 | 13:37h

Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement

---

Análise de especialista | Toxicidades vasculares de novas terapias oncológicas.

25 Mai, 2022 | 13:26h

Vascular Toxicities of Novel Cancer Therapies – American College of Cardiology

---

Diretrizes de prática clínica NCCN em oncologia | Atualizações de 2022.

24 Mai, 2022 | 11:43h

NCCN Clinical Practice Guidelines in Oncology: 2022 Updates – The ASCO Post

---

Viabilidade de identificar e transcrever o genoma completo em cânceres pediátricos e em adultos jovens.

24 Mai, 2022 | 11:30h

Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers – Nature Communications

Comentários:

Researchers show the feasibility of a comprehensive sequencing approach in pediatric and young adult cancers – News Medical / Memorial Sloan Kettering Cancer Center

Study Points to Expanded Genomic Testing to Benefit Children and Young Adults With Cancer – The ASCO Post

 

Comentário da autora no Twitter (fio – clique para saber mais)

Feasibility of clinical whole genome and transcriptome sequencing (WGTS) in oncology. A 🧵 on our latest study published in Nature Communications today:https://t.co/6007GkYDAc

— Elli Papaemmanuil, PhD (@PapaemmanuilLab) May 18, 2022

 

---